Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | CAR-T for ALL: the impact of bridging therapy

Karlo Perica • 1 Jun 2019
ASCO 2019
Acute Lymphoblastic Leukemia

Karlo Perica, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the impact of bridging strategies in patients with R/R acute lymphoblastic leukemia (ALL) at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Karlo Perica

1:00
CAR-T for ALL: bridging options and choices
Karlo Perica • 1 Jun 2019
0:59
Characterizing bridging strategies for CAR T-cell therapy
Karlo Perica • 1 Jun 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals